The designers of heart disease trials should ensure that they recruit enough women to reveal reliably whether they are responding to the drugs in a different way from men, according to research published on line today (Tuesday, 2 August) in Europes leading cardiology journal, the European Heart Journal.
Women are under represented in most clinical studies, so the data and the results are less well documented for them, according to Dr Verena Stangl, senior author of the paper, who is from the Charité Hospital, Humboldt-University Berlin, Germany.
Dr Stangl, who is Professor of Cardiology (Molecular Atherosclerosis) at the hospitals Department of Cardiology, Angiology and Pneumology, said that although the percentage of women in studies of coronary heart disease had risen since the mid 1980s to reflect the prevalence of CHD in women, they were still under represented in trials involving coronary artery disease, arterial hypertension and heart failure.
"Because too few women participate in heart disease trials we are not sure whether they really benefit from some therapeutic strategies that have shown clinical benefit in trials conducted predominantly in men. So, we prescribe drugs to women adapted from evidence-based data obtained from studies conducted mainly in men and we do not really know whether we help or harm the female patients. Take one example: as we have no prospective data for digitalis in female patients, its unclear whether it is really linked to increased mortality among women or whether this increase is an effect only of an overdose, and therefore whether they would benefit from lower doses adapted to their weight."
Dr Stangl said women have historically been under-represented in trials. The main reason was probably because cardiovascular diseases have erroneously been perceived as male diseases. As most cardiovascular diseases tend to occur later in women, co-existing health problems and age limitations on trials have worked against their inclusion. Late diagnosis due to different and more ambiguous symptoms was another reason and, for women of child-bearing age, the risks of damaging a foetus if a woman became pregnant, led to exclusion.
Dr Stangls call for increasing the numbers of women in heart trials is backed in an editorial also published in EHJ on line today by specialists from the University of Pavia in Italy.
Senior author Dr Silvia Priori, Associate Professor of Cardiology at the University of Pavia, said that research published this year showed that of 300 new drug applications to the US Food and Drug Administration (FDA) between 1995 and 2000 only 163 included an analysis according to gender. Yet 11 of the drugs involved showed a difference in the way a womans body dealt with the drugs compared with a mans (the pharmacokinetics).
"These differences underlie the importance of studying women as well as men in major cardiovascular trials. Most of the progress in this direction has occurred in the USA as a direct consequence of the commitment of funding agencies that have provided economic support only when a balanced gender presence was assured in the design of a trial," said Dr Priori.
She urged scientific societies to play a major role in ensuring trials investigate gender- specific response to therapy. The Europe Society of Cardiology (ESC), which publishes the European Heart Journal, recently developed the Women at Heart programme to organise initiatives targeted at promoting research and education in cardiovascular disease in women.
The ESC Congress in Stockholm (3-7 September) will focus specially on women and cardiovascular diseases, said Dr Priori, and the ESC is to perform gender-based analyses of data in the Euro Heart Survey – the programme that monitors clinical practice in Europe. She added that, in future, the ESC will work to promote a larger representation of women in clinical trials to provide missing data on gender differences in response to drug therapy.
 Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. European Heart Journal. doi: 101093/eurheartj/ehi397.
 Gender-specific prescription for cardiovascular diseases? European Heart Journal. doi: 10.1093/eurheartj/ehi428.
Margaret Willson | alfa
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration
"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...
Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.
Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
16.01.2017 | Power and Electrical Engineering
16.01.2017 | Information Technology
16.01.2017 | Power and Electrical Engineering